Shows
Vital Health PodcastJohn Murphy: Generics, Biosimilars, and U.S. PolicyIn this episode of the Vital Health Podcast, host Duane Schulthess speaks with John Murphy, President and CEO of the Association for Accessible Medicines (AAM), to discuss how U.S. purchasing dynamics and thin margins drive shortages, the evolving biosimilar landscape amid insurer vertical integration, the Inflation Reduction Act (IRA)’s ripple effects on plan risk and rebates, Most Favored Nation (MFN) policy proposals, and what it will take to reshore capacity while preserving competition and patient access. Key Topics: Generic Pricing Pressures: Purchaser consolidation, sterile injectables, margin squeeze, and exits. Drug Shortage Ec...
2025-10-0844 min
Not So Different: A Podcast from The Center for BiosimilarsFollow the Science: Bridging the Biosimilar GapThis special vodcast series provided by The Center for Biosimilars® was developed in partnership with the AAM and Biosimilars Council. Check out part 1 of the series featuring a discussion between Giuseppe Randazzo and Craig Burton, former executive director of the Biosimilars Council and current senior vice president of government affairs and policy at Fresenius Kabi.
References
Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
2025-07-2826 min
Vital Health PodcastJocelyn Ulrich: PBMs, Policy Risk, and Biopharma’s FutureIn this Vital Health Podcast, host Duane Schulthess speaks with Jocelyn Ulrich, Vice President of Policy and Research at PhRMA, to discuss the far-reaching implications of current U.S. drug pricing and reimbursement policies. With a unique journey from opera stages to Senate testimony, Ulrich brings both strategic acumen and firsthand experience in navigating complex policy terrain. The conversation explores PBM consolidation, the fallout from the Inflation Reduction Act, vertical integration in biosimilars, and looming tariff threats - all through the lens of innovation, patient access, and economic resilience. Key Topics PBM Consolidation Concerns: Three PBMs...
2025-06-1131 min
Pharmacy Podcast Network10 Years of Biosimilars: A Decade of Progress and a Bright Future | Cardinal Health™ Counter Talk™ PodcastJoin us as we celebrate 10 years of biosimilars. In this episode of The Counter Talk™ Podcast host Jason Callori speaks with Dracey Poore, Director of Biosimilars at Cardinal Halth to discuss the evolution of biosimilars and their impact on the healthcare landscape. Dracey shares valuable information on it's importance within the market and role of pharmacists. Click here to download the report and learn more.
https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/biosimilars-report.html
2025-06-1033 minNot So Different: A Podcast from The Center for BiosimilarsEscaping the Void: All Things Biosimilars With Craig & G
REFERENCE
Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
2025-05-0531 min
Healthcare NOW Radio Podcast Network - Discussions on healthcare including technology, innovation, policy, data security, telehealth and more. Visit HealthcareNOWRadio.comUnscripted The AMCP Podcast - IBD: Innovations, Challenges, and the Future of CareIBD Innovations, Challenges, and the Future of Care
On this episode host Fred Goldstein invites Casey Koch, PharmD, Clinical Pharmacy Coordinator at Select Health. We explore the discuss the evolving landscape of inflammatory bowel disease (IBD), including the latest treatment advancements, guideline updates, and the role of managed care pharmacy in optimizing patient outcomes. From biologics to biosimilars, personalized medicine, and health disparities, we dive deep into the complexities of IBD management and what the future holds for patients and providers alike.
Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like...
2025-03-0917 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars in Action: Market Shifts, Legal Insights, and FDA ApprovalsShow notes
1. Jeremias S. A banner year for biosimilars: The 19 FDA approvals from 2024. The Center for Biosimilars. January 21, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/a-banner-year-for-biosimilars-the-18-fda-approvals-from-2024
2. Jeremias S. FDA approves Celltrion's Avtozma as third tocilizumab biosimilar. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/fda-approves-celltrion-s-avtozma-as-third-tocilizumab-biosimilar
3. Jeremias S. Senators introduce bipartisan legislation to protect skinny labeling. The Center for Biosimilars. January 2, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/senators-introduce-bipartisan-legislation-to-protect-skinny-labeling
4. Jeremias S. FTC releases second report on PBMs meddling in generic drug markets. The Center for Biosimilars. January 19, 2025. Accessed February 7, 2025. https://www...
2025-02-0914 minNot So Different: A Podcast from The Center for BiosimilarsThe Top 5 Most-Listened to Podcasts of 2024Here are the top 5 episodes of Not So Different from 2024.
Number 5: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
Number 4: Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
Number 3: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
Number 2: Biosimilars in America: Overcoming Barriers and Maximizing Impact
Number 1: Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
2024-12-2905 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Gastroenterology Roundup for November 2024—Podcast Edition
Show Notes
1. Jeremias S. Skyrizi overtakes Humira: “product hopping” leaves biosimilar market in limbo. The Center for Biosimilars. November 7, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/skyrizi-overtakes-humira-product-hopping-leaves-biosimilar-market-in-limbo
2. Jeremias S. Celltrion sets sights on 2030 with expanded biosimilar portfolio, market reach. The Center for Biosimilars. November 6, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/celltrion-sets-sights-on-2030-with-expanded-biosimilar-portfolio-market-reach
3. Ferreri D. Making the cost of IBD care sustainable. The Center for Biosimilars. November 2, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/making-the-cost-of-ibd-care-sustainable
4. Ferreri D. Achieving PFS in advanced gastric cancer with HLX02 biosimilar, chemotherapy. The Center for Biosimilars. November 23, 2024. Accessed November 27, 2024. https://www.c...
2024-12-0105 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Development Roundup for October 2024—Podcast EditionShow notes
1. Jeremias S. Strengthening the supply chain: key insights from FDA commissioner Dr Robert Califf. The Center for Biosimilars®. October 25, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/strengthening-the-supply-chain-key-insights-from-fda-commissioner-robert-califf
2. Jeremias S. FDA and industry experts unpack biosimilar device requirements. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/fda-and-industry-experts-unpack-biosimilar-device-requirements
3. Jeremias S. Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/calling-for-unified-biosimilar-standards-stronger-education-at-grx-biosims
4. Jeremias S. Unifying standards: the need for streamlined biosimilar development. The Center for Biosimilars. October 22, 2024. Accessed November 1, 2024. https://www.cente...
2024-11-0305 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Policy Roundup for September 2024—Podcast EditionShow notes
1. FDA Approves Pavblu for Retinal Conditions
2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
4. The Future of Biosimilar Gene Therapies: Key Issues and Potential
5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share
6. The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
7. France Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
2024-10-0607 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Business Roundup for August 2024—Podcast EditionShow notes
1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024
2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars
4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
5. FDA Approves Biosimilar Enzeevu for Eye Conditions
6. Manitoba Adopts Biosimilar Switching Policy
7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline
2024-09-0105 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Policy Roundup for July 2024—Podcast EditionShow notes
1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara
2. Ahzantive Receives FDA Approval as New Eylea Biosimilar
3. FDA Approves Epysqli as Second Soliris Biosimilar
4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
5. Biosimilars and Employers: Strategies for Success
6. Learning the Lingo of Biologics and Biosimilars Is Critical
7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings
8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
2024-08-0405 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars in America: Overcoming Barriers and Maximizing ImpactShow notes
To learn more about Cencora and their efforts, click here.
To learn more about the Inflation Reduction Act's impact on biosimilars, click here.
2024-07-2127 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Oncology Roundup for June 2024—Podcast EditionShow notes
1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships
2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology
3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars
6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars
7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability
8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity
2024-07-0706 minNot So Different: A Podcast from The Center for BiosimilarsBreaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti ApprovedTo learn more about the approval of denosumab-bddz, click here.
To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteoporosis treatment, click here.
To learn more about the ROSALIA study (NCT05405725), click here.
Extra content: To read more about the Biosimilars Council position paper on how to improve biosimilar development, click here.
2024-06-1627 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Gastroenterology Roundup for May 2024—Podcast EditionShow notes
FDA Approves High-Concentration Cyltezo
Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars
DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use
Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD
New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
2024-06-0205 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Policy Roundup for April 2024—Podcast EditionShow notes
FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
2024-05-0505 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Dermatology Roundup for March 2024—Podcast EditionShow notes
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
Adalimumab Expenditures in Countries With and Without Available Biosimilars
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
2024-03-3104 minNot So Different: A Podcast from The Center for BiosimilarsDecoding the Patent Puzzle: Navigating the Legal Landscape of BiosimilarsShow notes
To read more of Ha Kung's thoughts on the US patent system and its role in the biosimilar landscape, click here.
To learn more about Congress' role in addressing AbbVie's alleged anticompetitive practices regarding adalimumab products, click here.
To learn more about the suit filed by CareFirst BlueCross BlueShield regarding ustekinumab biosimilar delays, click here.
To learn more about the settlements that have resulted in the market delay of ustekinumab biosimilars, click here.
To learn more about lawsuits involving AbbVie that led to the delayed market entrance of adalimumab biosimilars, click here.
...
2024-03-1720 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Rheumatology Roundup for February 2024—Podcast EditionShow notes
FDA Approves 10th Adalimumab Biosimilar, Simlandi
Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates
Vizient Report Emphasizes Biosimilar Successes, Impact of Inflation on Drug Spend
Eye on Pharma: VA Picks Hadlima; Biocon, Sandoz Partnership; A Stelara Settlement Abroad
Eye on Pharma: Celltrion Biosimilars Win Tenders; Oral Ustekinumab Device Passes Phase 1 Trial
Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials
Adalimumab Treatment May Impact Antibody Levels After COVID-19 Vaccination
2024-03-0305 minNot So Different: A Podcast from The Center for BiosimilarsExploring the Biosimilar Horizon: Julie Reed's Predictions for 2024For more information on BsUFA III, click here.
For more information on the 1-year anniversary of adalimumab biosimilars in the US, click here.
To listen to more of Julie Reed's thoughts on the US biosimilar industry and streamlining development, click here.
To learn more about the Biosimilars Forum, click here.
2024-02-1825 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Gastroenterology Roundup for January 2024—Podcast EditionHappy Birthday Adalimumab Biosimilars: Reflecting on the First Year of US Competition
EMA Approves First Ustekinumab Biosimilar, Uzpruvo
Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars
IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe
IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition
Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings
Biosimilar SB5 Matches Originator in Safety, Efficacy for Inflammatory Diseases After Switching
Postapproval Pharmacovigilance Review Confirms Comparable Safety Between Sandoz Biosimilars, Originators
2024-02-0405 minNot So Different: A Podcast from The Center for BiosimilarsA New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and BeyondShow notes
To learn more about the prospect for Neulasta OnPro biosimilars, click here.
To learn more about how the IRA will impact biosimilars, click here.
To learn more about the dual-pricing strategy being used for adalimumab biosimilars, click here.
To hear Brian's insight into how the ophthalmology biosimilar industry is developing, click here.
To listen to previous Not So Different episodes featuring more of Brian's insight into how the adalimumab market will develop and biosimilar pricing trends, click here or here.
2023-12-3119 min
Praxiswissen2Go – der Podcast für medizinische AssistenzberufePraxiswissen2Go – Folge 14: Biologika und BiosimilarsWas sind Biologika eigentlich, und wie unterscheiden sie
sich von Biosimilars? Worauf kommt es im Praxisalltag bei Biologika-Therapien an?
Und warum solltet ihr bei diesem Thema selbst up to date sein?
Dazu informieren euch Fachkräfte, die sich mit
chronisch-entzündlichen Erkrankungen und dem Umgang mit Betroffenen bestens
auskennen. Alle drei haben langjährige Erfahrung mit Biologika und Biosimilars
und geben euch aus unterschiedlichen Fachgebieten konkrete Tipps für die Praxis,
zum Beispiel:
Ø Was ist vor einer Biologika-Therapie zu klären?
Ø Wie werden Biologika verabreicht, welche Form
bietet sich bei welchen Patient:innen an?
2023-12-2119 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilar Oncology Roundup for November 2023—Podcast Edition Show notes
Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?
Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices
Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
Denosumab Biosimilar Demonstrates Positive Safety Results in Chinese Study
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
Similar Safety Profiles of Biosimilar, Reference Pegfilgrastim Found in Clinical Studies
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
2023-12-0305 min
Managed Care CastManaged Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 2Today we are bringing you part 2 of a 2-part podcast series on opportunities for biosimilars, specifically adalimumab biosimilars, in dermatology, gastroenterology, and rheumatology.
The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute. The topics of conversation for today’s podcast include implementation of biosimilars in patients with no history of reference biologic use, insights on switching patients from the reference to the biosimilar, auto-substitution, impact of biosimilar utilization on payers and pharmacy benefit managers, and more.
2023-11-2119 minNot So Different: A Podcast from The Center for BiosimilarsGlobal Biosimilars Week: Dr Fran Gregory Explores the Growing Oncology Biosimilar Space, Previews FutureShow notes
For more information on Global Biosimilars Week, click here.
To read our article series in honor of Global Biosimilars Week, you can check out part 1, part 2, and part 3 here.
To watch the webinar The Center for Biosimilars collaborated with IGBA for Global Biosimilars Week, click here.
2023-11-1926 minManaged Care CastManaged Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 1Today we are bringing you part 1 of a 2-part podcast series on opportunities for biosimilars, specifically adalimumab biosimilars, in dermatology, gastroenterology, and rheumatology.
The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute. The topics of conversation for today’s podcast include the provider and payer considerations for transitioning patients to biosimliars, challenges associated with biosimilars, approaches to prescribing biosimilars over reference products, and more.
2023-11-1019 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilar Business Roundup for October 2023—Podcast Edition
FDA Approves First Subcutaneous Infliximab Product
Abrilada Approved as Second Interchangeable Humira Biosimilar
Eye on Pharma: New GI Data and Byooviz Interchangeability Propel Biosimilars Into the Future
Biosimilars Check-In: BI Launches Unbranded Adalimumab; New Omalizumab Deal; CRL for Insulin Aspart
Eye on Pharma: Another CRL for Alvotech; Cimerli’s Growing Market Share; BBCIC Awarded Grant
Samsung Bioepis Presents Positive Phase 3 Data on Aflibercept Candidate
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
2023-11-0505 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Regulatory Roundup For September 2023– Podcast Edition
Show Notes
House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics
Part 2: FDA Workshop Shares Manufacturer Perspective on the Value of Clinical Efficacy Testing
Part 1: FDA Workshop Highlights Global Regulatory View on Biosimilar Development
Part 3: BioRationality—FDA Webinar on Biosimilars Efficacy Testing Marks Major Step Forward
Alvotech’s Stelara Biosimilar Approved in Japan
EC Approves First MS Biosimilar; Coherus Receives CRL for Neulasta Onpro Competitor
European Commission Approves First Aflibercept Biosimilar
Regulatory Updates From Around the Globe Provide Hope for Biosimilars
2023-10-0204 minNot So Different: A Podcast from The Center for BiosimilarsDr. Fran Gregory's Sizes Up the US Adalimumab Market: Will Biosimilars See Success?To read more about Dr. Gregory's commentary piece, click here.
To read more about Cardinal Health's 2023 Biosimilars Report, click here.
To learn more about adalimumab biosimilars, click here.
To learn more about the adalimumab biosimilars that have launched so far in the US:
Click here for the launch of Amjevita
Click here for the launches of Hyrimoz, Hadlima, Yusimry, and Cyltezo
Click here for the launch of Yuflyma
Click here for the launches of Idacio and Hulio
2023-09-1822 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Business Roundup For August 2023– Podcast Edition
Show Notes
FDA Approves First MS Biosimilar
Stelara and Enbrel Chosen for IRA Price Negotiation
Biocon Biosimilar Quarterly Sales Up 106%
STADA Earnings Project Record Breaking Profits for 2023
Despite Global Increase in Amjevita Sales, US Sales Dropped 63%
Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility
Cardinal Health Exec: How Adalimumab Biosimilars Can Reshape the US Health Care Industry
2023-09-0305 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Immunology Roundup for July 2023- Podcast Edition
Show Notes
First Round of Adalimumab Biosimilar Launches in July
Celltrion Launches Yuflyma on the US Market
US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market
Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending?
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price
Price Reductions of TNF Inhibitors Across Europe After First and Second Biosimilar Launches
Multiple Infliximab Biosimilar Switches Were Safe, Effective
Adalimumab Bi...
2023-08-0604 minNot So Different: A Podcast from The Center for BiosimilarsAdalimumab Biosimilars Take Center Stage: A Game Changer for IBD TreatmentShow notes
To learn more about the adalimumab products that have launched in the US so far, click here, here, here, or here.
Crohn's & Colitis Educational Resources:
Biosimilars: What You Should Know
What is a Biosimilar Video
2023-07-1616 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Business Roundup for June 2023—Podcast Edition
Show notes
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
Roundup: Coherus Resolves AbbVie Dispute; Bio-Thera Solutions and Celltrion Expand Respective Partnerships
Eye on Pharma: First PBM to Cover Yusimry; Celltrion to Test Ocrevus Biosimilar; Another Stelara Settlement
The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare
Alvotech, Advanz Pharma Extend Partnership for Biosimilars in Europe
Medicare 340B Program May Be Reducing Biosimilar Uptake
Sandoz Roadmap Aims to Increase Worldwide Biosimilar Adoption by 2030
2023-07-0204 min
Not So Different: A Podcast from The Center for BiosimilarsBiosimilars Immunology Roundup for May 2023—Podcast Edition
Show Notes
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology
Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption
Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders
Tocilizumab Biosimilar LZM008 Demon...
2023-06-0404 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Rheumatology Roundup for April 2023—Podcast Edition
Biosimilars Check In: Vegzelma Launch, BLA Acceptances, China Approval
FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar
Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD
Study on Nonmedical Switching for Adalimumab Biosimilars Warns About Nocebo Effect
Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
Study Reveals Factors That Dissuade Commercial Plans From Covering Biosimilars
2023-04-3004 minNot So Different: A Podcast from The Center for BiosimilarsPipelines and Preparation: How the US Can Prepare for More RA BiosimilarsTo learn more about biosimilars to treat RA, click here.
To learn more about rheumatologists’ perceptions about RA biosimilars, click here.
To learn more about incentives for prescribing biosimilars, click here.
To learn more about infliximab biosimilar adoption, click here.
To learn more about the influx of adalimumab biosimilars to the US market, click here.
To learn more about ustekinumab biosimilars, click here.
2023-04-1618 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Policy Roundup for March 2023—Podcast Edition
Show notes
Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy
Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy
Policy Recommendations for Improving Biosimilar Uptake in Belgium
Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies
Dr Ivo Abraham Column: The 2022 WHO Biosimilar Guidelines—Loosening the Reins or Changing the Track? Part 2
The Increasing Access to Biosimilars Act of 2023 Introduced to Congress
Published Data Coupled With Real-world Evidence Show Safety of Biosimilar-to-Biosimilar Switching
Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Juli...
2023-04-0203 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Gastroenterology Roundup for February 2023—Podcast Edition
Show notes
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://ww...
2023-03-0505 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Rheumatology Roundup for January 2023—Podcast Edition
Show notes
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Canada Approves High-Concentration Humira Biosimilar
https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar
Celltrion Submits BLA for Infliximab Biobetter
https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar
Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study
https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study
China's NMPA Approves Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar
...
2023-02-0505 minNot So Different: A Podcast from The Center for BiosimilarsSeeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology BiosimilarsShow notes:
To check out part 1 of this interview series (written Q&A with Samsung Bioepis’ Kyung-Ah Kim), click here.
Coming soon, part 3 will be a video interview about the initial market response to ophthalmology biosimilars and how industry leaders can work together to increase uptake.
To learn more about the approval of Cimerli, click here.
To learn more about ophthalmology biosimilars, click here.
To learn more about interchangeability, click here.
To learn more about clinical efficacy testing, click here.
To learn more about our LinkedIn Live event on ophthalmology biosimilars, you can re...
2023-01-2913 min
ClinPharmPodBuilding on BiosimilarsClinical Pharmacology & Therapeutics recently published its first themed issue of 2023 – Innovations in Biosimilars. Join Editor-in-Chief Dr. Piet van der Graaf and Guest Editor Yow-Ming Wang as they discuss what papers stood out to them, their thoughts around the growing importance of biosimilars in Clinical Pharmacology, and how the editorial team developed that […]
2023-01-2314 minNot So Different: A Podcast from The Center for BiosimilarsGoodbye 2022—The Top 10 Biosimilars Stories of the YearTop 10 stories of the year:
10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar
9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA
8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology
6. Report: Biosimilar Competition in Europe
5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options
- For the whole series, click here.
4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira
3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab
2. FDA...
2023-01-0105 minNot So Different: A Podcast from The Center for BiosimilarsNew Year, New Hurdles: What's in Store for Biosimilars in 2023To read more about adalimumab biosimilars, click here.
To read more about ophthalmology biosimilars, click here.
To learn more about the Inflation Reduction Act’s impact on biosimilars, click here.
To read more about the reauthorization of the Biosimilars User Fee Amendment, click here.
To learn more about interchangeability, click here.
2022-12-1818 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Regulatory Roundup for November 2022—Podcast Edition
Show notes
Rezvoglar Becomes Second Interchangeable Insulin Biosimilar
Biosimilar Business Recap: Progress for Insulin in Europe, Canada; Biocon Biologics' Viatris Acquisition Completed
The European Union Gains Another Ranibizumab Biosimilar
Alvotech Snags Australian Approval for Adalimumab Biosimilar
Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Organon Launches in Canada
Senator Introduces Bill to Rid Switching Study Requirements for Interchangeability
BioRationality: A Dr Sarfaraz Niazi Column—FDA Launches Biosimilar Regulatory Science Program
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
2022-12-0404 minNot So Different: A Podcast from The Center for BiosimilarsWhat Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars
Show notes:
To read more about Amgen’s Biosimilar Trends Report, click here.
To learn more about the Inflation Reduction Act’s impact on biosimilars, click here.
To see more of Chad’s takeaways from older version of Amgen’s Biosimilar Trends Report, click here.
To learn more about tender systems, click here.
To check out the last episode of Not So Different, click here.
2022-11-2719 minNot So Different: A Podcast from The Center for BiosimilarsAAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?This episode is made in conjunction with the third annual Global Biosimilars Week, a biosimilar awareness campaign hosted by the International Generic and Biosimilar Association (IGBA) from November 14 through November 18. The Center for Biosimilars is a proud media partner for Global Biosimilars Week and you can check all our social media pages to view our coverage of the event.
To learn more about Global Biosimilars Week, click here.
To learn more about BsUFA III, click here.
To learn more about the Inflation Reduction Act, click here.
To learn more about President Biden’s executive order, cl...
2022-11-1319 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Policy Roundup for October 2022—Podcast EditionShow notes
Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Policy
Advocacy Organization Calls for Ontario to Switch Patients to Biosimilars
BioRationality: a Dr Sarfaraz Niazi Column—The EMA Declares Biosimilars Interchangeable
Biden Authorizes Update to the Biosimilar User Fee Act Through 2027
New Bill Aims to Remove Barriers to Interchangeable Biosimilars
Amgen Report: Biosimilars Have Saved $21 Billion in 6 Years
It’ll Take a Village: Collaborative Efforts Needed to Increase Ophthalmology Biosimilar Uptake
Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency
Dr Ryan Haumschild: What Health Systems Can Learn From...
2022-11-0605 minNot So Different: A Podcast from The Center for BiosimilarsOrder of Operations: Managing Biosimilars While Maintaining Operational Efficiency
Show notes:
To read more of Kathy’s thoughts on the practice perspective regarding biosimilars, click here.
To learn more about automatic substitution policies, click here.
To learn more about some of the challenges clinicians could face next year as adalimumab biosimilars enter the market, click here.
To learn more about prescription behaviors regarding biosimilars, click here.
To listen to another podcast episode on a tool that can improve infusion center efficiency, click here.
2022-10-1613 minNot So Different: A Podcast from The Center for BiosimilarsBiosimilars Oncology Roundup for September 2022—Podcast Edition
Show notes
FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar
https://www.centerforbiosimilars.com/view/fda-approves-stimufend-the-us-sixth-pegfilgrastim-biosimilar
FDA Approves Celltrion Biosimilar for Avastin, Vegzelma
https://www.centerforbiosimilars.com/view/fda-approves-celltrion-biosimilar-for-avastin-vegzelma
Oncology, Ophthalmology Biosimilars Progress in Europe
https://www.centerforbiosimilars.com/view/oncology-ophthalmology-biosimilars-progress-in-europe
Biosimilars Check-In: Canada Approves Third Etanercept; Prestige Withdraws Trastuzumab Application
https://www.centerforbiosimilars.com/view/biosimilars-check-in-canada-approves-third-etanercept-prestige-withdraws-trastuzumab-application
Coherus Rep Shares Competition Strategy for Adalimumab, Pegfilgrastim Biosimilars
https://www.centerforbiosimilars.com/view/coherus-rep-previews-interchangeable-ranibizumab-adalimumb-launches-on-pro-competitor?seriesVid=5
Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts
https://www.centerforbiosimilars.com/view/policy-harmonization-clarification-could-aid-biosimilar-uptake-efforts
...
2022-10-0204 minNot So Different: A Podcast from The Center for BiosimilarsHow Heath Policy Can Impact Adoption for Adalimumab BiosimilarsThis special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars.
To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here.
To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here.
To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here.
To listen to the other podcast in this series, “What Will Year 1 Look L...
2022-09-2522 minNot So Different: A Podcast from The Center for BiosimilarsWhat Will Year 1 Look Like for Adalimumab Biosimilars?This special episode is part of a larger series called “WHEN CHOICE ARRIVES: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars.
To read part 1 of this series, “Biosimilars to Bring a Bumper Crop of Adalimumab Options,” click here.
To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here.
To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here.
To listen to the other podcast in this series, “What Will Year 1 Look L...
2022-09-1122 minNot So Different: A Podcast from The Center for BiosimilarsHow Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab MarketTo learn more about the hype regarding adalimumab biosimilars in the US, click here.
To see which biosimilars have been approved by the FDA, click here.
To read more on PBMs and their influence on biosimilar uptake, click here.
To read Manolis’ 2016 paper, click here.
2022-07-2412 minNot So Different: A Podcast from The Center for BiosimilarsDr. Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology BiosimilarShow notes:
To learn more about the US launch of Byooviz, click here.
To read more about the anticipation for ophthalmology biosimilars, click here.
To read more of Dr. Oskouei’s comments on “Round 2,” click here.
To learn more about the EU approval of Byooviz, click here.
To learn more about the Canadian approval of Byooviz, click here.
To read more on the anticipation for aflibercept biosimilars, click here.
2022-07-1014 min
Pharmacy Podcast NetworkPharmacists Impact on Biosimilar Adoption with special guest Sonia Oskouei, PharmDAs an innovative method to improve the affordability of costly biological therapies, there's new medication products being developed with the needed approval of the Food and Drug Administration (FDA) for biological products that are “highly similar” (biosimilar) to or interchangeable with traditional drug developed products. Biosimilars are not completely identical to the innovator product because of the large molecular size, complexity and proprietary nature of the manufacturing process, and inherent variability of all biopharmaceuticals.
Dr. Sonia Oskouei, PharmD, BCMAS, DPLA is Vice President of Biosimilars at Cardinal Health. Sonia shares her experiences in the biosimilars sector of drug development and share...
2022-07-0929 min
Pharmacy Podcast NetworkBiosimilars and Interchangeability | Cardinal Health™ Counter Talk™ PodcastJoin Host Jason Callori and special guests Sonia Oskouei and Jeff Baldetti from Cardinal Health as they discuss Biosimilars evolution in the pharmaceutical industry and the benefits that they can have for pharmacists and patients alike. You can subscribe to the Cardinal Health™ Counter Talk™ Podcast on Spotify, Apple Podcasts and wherever you listen to your favorite podcasts.
Learn more about your ad choices. Visit megaphone.fm/adchoices
2022-05-3133 minNot So Different: A Podcast from The Center for BiosimilarsNot So Different: Tactics for Increasing Patient and Provider Confidence in BiosimilarsTo listen to part 1 of this podcast, click here.
To listen to part 2 of this podcast, click here.
To learn more about building patient confidence in biosimilars, click here.
To learn more about how education can improve patient confidence, click here.
2021-10-1004 minNot So Different: A Podcast from The Center for BiosimilarsNot So Different: How 1 Practice is Addressing Biosimilar Concerns Over Savings, Safety, and EfficacyTo listen to part 1 of this podcast, click here.
To learn more about building physician confidence in biosimilars, click here.
For more on how switching to biosimilars can impact budgets and savings, click here.
2021-10-0305 minNot So Different: A Podcast from The Center for BiosimilarsNot So Different: Gary Lyman, MD Details What Needs to Be Done to Ensure Physician Confidence in BiosimilarsA major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence on the safety and efficacy of biosimilars compared with reference products in patients with cancer, for whom the stakes are high when choosing a therapeutic or supportive agent. Additionally, some clinicians worry about having to stock multiple biosimilars for a single reference product. These may require different storage conditions and increase the risk of administering the wrong agent, creating financial risk for the practice.
We sat down with Gary Lyman, MD...
2021-08-1516 minNot So Different: A Podcast from The Center for BiosimilarsNot So Different: What the Generics Industry Can Tell Us About the Future of BiosimilarsTo learn more about the Hatch-Waxman Act, click here.
To learn more about how biosimilars compare with the generics market, click here.
To learn more about the challenges that both the biosimilars and generic markets face, click here.
2021-07-1811 minNot So Different: A Podcast from The Center for BiosimilarsWhat’s Stopping Physicians From Prescribing Biosimilars?To learn more about struggles regarding physician decisions on biosimilars, click here.
For more on payer influence on prescribing patterns, click here.
For more on NCCN’s biosimilar work, click here.
2021-04-2518 minNot So Different: A Podcast from The Center for BiosimilarsAnar Dossa Discusses Success and Savings With British Columbia’s Biosimilars InitiativeTo learn more about phase 3 of the BC Biosimilars Initiative, click here.
To learn more about recent biosimilar launches in Canada, click here or here.
To learn more about biosimilar switches in Canada, click here.
To learn more about other Canadian province’s biosimilar plans, click here.
To learn more about Pacific Blue Cross’s success with the program, click here.
2021-02-2812 minNot So Different: A Podcast from The Center for BiosimilarsKanika Monga, MD, and Angus Worthing, MD, Discuss ACR Survey on Biosimilars and COVID-19To learn more about the ACR’s survey, click here.
To learn more about COVID-19’s impact on biosimilars, check out our ebook here.
2020-10-1112 minNot So Different: A Podcast from The Center for BiosimilarsJulie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's ImpactTo learn more about COVID-19's impact on biosimilars, click here.
To learn more about biosimilar education, click here.
To learn more about step therapy, click here.
To learn more about payer interference on preferred drugs, click here.
2020-09-2710 minNot So Different: A Podcast from The Center for BiosimilarsCheryl Larson on How Employers Can Get Biosimilars Added to Their Health PlanTo learn more about MBGH's call to action for employers, click here.
To learn more about MBGH's biosimilars report, click here.
To learn more about Midwest Business Group on Health, click here.
2020-09-0610 minNot So Different: A Podcast from The Center for BiosimilarsApril Breyer Menon Discusses 2 Potential Bills to Aid Biosimilar UptakeIt’s no secret that the US biosimilar industry has had a slow start in terms of uptake, but much of that setback is due to barriers caused by originator manufacturers taking advantage of current legislation. Although, the Hatch-Waxman Act and the Biologic Price Competition and Innovation Act (BPCIA) established pathways to approval for both generic drugs and biosimilars, there is still much legislative work to be done in order to truly reap the benefits of biosimilars.
We sat down with April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to dis...
2020-05-2812 minNot So Different: A Podcast from The Center for BiosimilarsDr. Sang-Jin Pak Talks Biosimilar Markets: US vs EuropeIn April 2020, Samsung Bioepis launched Ontruzant, a biosimilar for trastuzumab, in the US market, in partnership with Merck. The company launched the same drug in Europe in 2018, and it was the first trastuzumab biosimilar in Europe. This earlier release of biosimilars in Europe is not an anomaly, as Europe has had a much easier time developing and launching biosimilars than the US thanks to their decade-long head start in the industry. We sat down with Dr. Sang-Jin Pak, the executive vice president of Samsung Bioepis’ Commercial Division to discuss the differences between the US and Europe.
2020-04-2503 min
Not So Different: A Podcast from The Center for Biosimilars"Not So Different": How the BPCIA Transition Will Impact Biosimilar UptakeOn March 23rd, 2020, the transition under the Biologics Price Competition and Innovation Act was complete, allowing products formerly classified as “small-molecule” drugs, including all insulin products, to be approved under the biologics regulatory pathway. This week on the podcast, we’re speaking with executive director of the Biologics and biosimilars collective intelligence consortium (also known as the BBCIC) , Cate Lockhart, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how this new transition will impact the market and uptake efforts.
2020-04-0910 minNot So Different: A Podcast from The Center for BiosimilarsEmployers Advocate for Lower Drug Costs Through BiosimilarsWith pharmaceutical spending at record levels, employers are looking for solutions and are hopeful that biosimilars can play a role in controlling costs. On this episode, we speak with representatives of EmployersRX, a new coalition made up of 3 employer groups that are advocating for measures that would provide relief for the largest purchasers of healthcare.
2020-01-1317 minNot So Different: A Podcast from The Center for BiosimilarsThe Year in US Regulatory Activity for BiosimilarsWhen it comes to US biosimilars, 2019 was a busy year for regulatory activity. This week on the podcast, we're rounding up the key developments of the year.
2019-12-2906 minNot So Different: A Podcast from The Center for BiosimilarsAt the American College of Rheumatology, a UK Perspective on BiosimilarsDuring the American College of Rheumatology’s recent 2019 annual meeting, we caught up with Paul Emery MD, FRCP, MA, FMedSci. Emery is the Versus Arthritis Professor of Rheumatology, University of Leeds, and the Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust in the United Kingdom. In this episode of the podcast, we’re sharing highlights of our interview with Emery about biosimilars.
2019-12-2207 minNot So Different: A Podcast from The Center for BiosimilarsAmerisourceBergen’s Sean McGowan Takes a Closer Look at US Biosimilar LaunchesWith us on the podcast to talk about recent and upcoming biosimilar launches is Sean McGowan, senior director of biosimilars at AmerisourceBergen. McGowen spoke with us about what the US biosimilars market needs now in order to thrive, and tells us which developments he'll be watching closely in 2020.
2019-12-1516 minNot So Different: A Podcast from The Center for BiosimilarsIs There a Role for Biosimilars in Value-Based Models?As fee-for-service models give way to value-based healthcare delivery models, US providers and patients alike can hopefully forward to lower healthcare costs, increased quality of care, and improved outcomes. But what role will biosimilars have to play in value-based care?
This week on the podcast, we're speaking with Jeffrey Scott MD, chief medical officer of Integra Connect, a company that uses cloud-based technologies and services that help specialty care providers optimize their performance in the ongoing shift to value-based models. Scott spoke with us about value-based contracting in the biosimilars context.
2019-11-2418 minNot So Different: A Podcast from The Center for BiosimilarsHealthyWomen Wants to Educate US Women About BiosimilarsIn October of this year, the nonprofit organization HealthyWomen, a group that seeks to educate women to make informed choices about their health, hosted its first Biosimilars and Women’s Health Science and Policy Forum. This week on the podcast, we’re speaking with one of the presenters from that meeting, Lisa Kennedy Sheldon, PhD, APRN, AOCNP, FAAN.
2019-11-1712 minNot So Different: A Podcast from The Center for BiosimilarsWhat's New in Biosimilars in GastroenterologyWith new research being presented, and with new biosimilars in the pipeline that target inflammatory bowel disease, October was a notable month for biosimilars in the gastroenterology space. This week on the podcast, we’re rounding up the top developments in gastroenterology for the month of October 2019.
2019-11-0308 minNot So Different: A Podcast from The Center for BiosimilarsStrategies for Biosimilar Developers in a Litigious US LandscapeIn August of this year, the US District Court for the District of New Jersey ruled in favor of Amgen in a long-running patent litigation concerning Sandoz’s biosimilar etanercept, Erelzi. As a result of that decision, biosimilar etanercept appears to be on a lengthy hold in the US market, and that has a number of biosimilar stakeholders concerned.
This week on the podcast, we’re speaking with Rick Lozano, vice president of Biosimilars and Integrated Business Development for AmerisourceBergen. We discuss the ruling in the case, its potential impacts on the healthcare system, and what drug makers can d...
2019-10-2718 minNot So Different: A Podcast from The Center for BiosimilarsAre We Ready for Biosimilar Rituximab in the United States?It’s widely expected that the United States will see launches of one or both of the FDA-approved biosimilars, Ruxience and Truxima, in the coming months, but just how ready is the United States to bring these products to the clinic, especially given the fact that subcutaneously administered reference rituximab has taken on such a key place in clinical practice, and given the fact that both biosimilars have so-called “skinny labels” because of issues related to intellectual property and exclusivities?
Over the past year, we’ve had the opportunity to explore these questions and more with a variety of exper...
2019-10-2011 minNot So Different: A Podcast from The Center for BiosimilarsWhat Have We Learned So Far About US Oncology Biosimilars?Among the biggest biosimilars news of this year was the launch of the first 2 anticancer biosimilars; stakeholders have been eager to see whether these products can jumpstart what has been described by some as a sluggish US market for biosimilar products. This week on the podcast, we're speaking with an expert who's sharing her insight into these developments in the oncology space.
Christina Corridon, MPH, MBA, is a principal at the professional services firm ZS Associates, where she is a leader in ZS' oncology practice and leads their biosimilars vertical. Christina joined us to talk about the state...
2019-10-1320 minNot So Different: A Podcast from The Center for BiosimilarsOneOncology Gives a Closer Look at Its Biosimilar AdoptionThe question of whether anticancer biosimilars will achieve strong uptake in the United States, and whether they will produce much-needed cost savings, is one that has pervaded the conversation about US biosimilars for some time. Shortly after Amgen launched the first 2 such agents, biosimilar trastuzumab and bevacizumab, OneOncology, a group that comprises 4 large community oncology practices and 100 sites of care, announced that it had made those 2 biosimilars preferred agents.
This week on the podcast, we’re speaking with Jeffrey Patton, MD, chief executive officer of Tennessee Oncology, a partner practice of OneOncology, and the President of Physician Services for...
2019-09-2910 minNot So Different: A Podcast from The Center for BiosimilarsWhere Are We Headed With Oncology Biosimilars? Vizient Weighs InIn its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs. This week on the podcast, we're speaking with Steven Lucio, PharmD, BCPS, associate vice president of clinical solutions and pharmacy program development at Vizient, on how oncology biosimilars are poised to make an impact.
2019-09-1517 minNot So Different: A Podcast from The Center for BiosimilarsHow a Value-Based Pathway Led to Increased Biosimilar UseIt's no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, but given the benefits that biosimilars can offer, some physicians are taking matters into their own hands with concerted efforts to bring biosimilars to the clinic. This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Health Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.
2019-09-0112 minNot So Different: A Podcast from The Center for BiosimilarsThe Biosimilars Council Says Patent Abuses Are Costing Biosimilar SavingsThe Biosimilars Council, a part of the Association for Accessible Medicines, recently issued a white paper in which it condemns abuses of the patent system that delay biosimilar competition. The group estimates that the financial impact of these delays has cost the US healthcare system $7.5 billion in lost savings since 2015. This week on the podcast, we’re speaking with Christine Simmon, executive director of the Biosimilars Council, about the paper, about patent thickets, and about what policy issues the organization wants to see addressed to move the needle on biosimilars.
2019-08-0418 minNot So Different: A Podcast from The Center for BiosimilarsWhat Did the First Half of 2019 Hold for Biosimilars?At the beginning of this year, we spoke with Laura Joszt, associate editorial director and the host of The American Journal of Managed Care’s podcast, Managed Care Cast, about where biosimilars stood at the end of 2018. Now, halfway through the year, we’re continuing that conversation with a look at how biosimilars have fared so far in 2019.
2019-07-1911 minNot So Different: A Podcast from The Center for BiosimilarsThe Biosimilars Forum Wants to Save the Healthcare System BillionsIndustry group the Biosimilars Forum recently put forth 3 policy proposals that it says could save the US healthcare system billions of dollars. This week on the podcast, we’ve invited the forum to tell us more about their proposals and other policy issues related to biosimilars. Joining us this week are Juliana Reed and Molly Burich. Reed is the vice president corporate affairs, global biosimilars lead at Pfizer, and is also president of the forum. Burich is director of public policy, biosimilars, and reimbursement at Boehringer Ingelheim, and an officer in the forum.
2019-07-0722 minNot So Different: A Podcast from The Center for BiosimilarsWhat's Holding Back Biosimilars? It May Not Be Pay-for-Delay DealsWhile pay-for-delay issues have been big news on Capitol Hill recently, some experts have questions about whether these kinds of settlements are really at the heart of delayed biosimilar competition, and they offer alternative ways to think about—and to fix—the problem. This week on the podcast, we’re speaking with 2 such experts, Imron Aly, JD, and Joel Wallace, JD. Both are partners at Schiff Hardin LLP and have extensive experience with Hatch-Waxman and biosimilars intellectual property issues.
2019-06-2323 minNot So Different: A Podcast from The Center for BiosimilarsA Look at Biosimilar Education Among European OncologistsThe cost of cancer care is on the rise worldwide, and biosimilars present one option for bringing down costs. However, those savings depend on adoption and use of biosimilars, and hesitancy to use these agents on the part of prescribers has been well documented. One newly published study reported on a survey conducted among European Society for Medical Oncology (ESMO) members and attendees of the 2017 ESMO Congress in Madrid, Spain, concerning biosimilars.
This week, we’re speaking with the study’s lead author, Rosa Giuliani, MD. She’s a medical oncologist at The Christie Hospital, Manchester, United Kingdo...
2019-05-1218 minNot So Different: A Podcast from The Center for BiosimilarsIs It Time to Give Up On Biosimilars?In a 2-part proposal published on the Health Affairs blog, a team of authors argued that efforts to induce lower prices through competition via biosimilars will inevitably fail. Instead, they write, prices for innovator biologics should be regulated by the US government after patent expiry.This week on the podcast, we’re talking with Mark Trusheim, MS, one of the authors of the proposal.
2019-04-2823 minNot So Different: A Podcast from The Center for BiosimilarsThe Community Oncology Perspective on Drug Pricing Proposals and BiosimilarsThe recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial director of The Center for Biosimilars®, caught up with Ted Okon, MBA, executive director of the Community Oncology Alliance.
2019-03-3115 minNot So Different: A Podcast from The Center for BiosimilarsAddressing Misinformation on BiosimilarsLast year, biosimilar developer Pfizer submitted a citizen petition to the FDA in which it called on the agency to issue guidance clarifying how drug sponsors can communicate about biosimilars. After the petition was filed, The Center for Biosimilars® invited an expert group of stakeholders to discuss misinformation about biosimilars as well as what steps are necessary to root out and address misinformation. This time on the podcast, we’re sharing a portion of that discussion with our listeners.
2019-03-2313 minNot So Different: A Podcast from The Center for Biosimilars"Not so Different:" The Supreme Court and US BiosimilarsThose who follow the biosimilars space closely are aware that, in the context of the US market, legal concerns regarding biosimilars can be just as regulatory ones in informing how drug makers do business.
One recent case that impacts on upon the biosimilars market was recently heard before the before the United States Supreme Court, and the outcome of the case will potentially impact drug makers seek patent protection for various aspects of their products.
In order to take a deeper dive into the case, and hear an expert perspective on its far-reaching impacts, this w...
2019-02-2220 minNot So Different: A Podcast from The Center for BiosimilarsWhere Do We Stand With Provider Education on Biosimilars?Recently, a new systematic review evaluating US and European provider awareness of biosimilars found a persistent lack of education on both sides of the Atlantic. This week, The Center for Biosimilars® is speaking with Sonia T. Oskouei, PharmD, one of the authors of the review, about the findings.
2019-02-0809 minNot So Different: A Podcast from The Center for BiosimilarsHow Biosimilars Advanced in 20182018 was a banner year for biosimilars, both in the United States and abroad. In this episode of the podcast, Laura Joszt, associate editorial director of The American Journal of Managed Care, interviews The Center for Biosimilars’ senior editor, Kelly Davio, about the key developments in biosimilars last year.
2019-01-2512 minNot So Different: A Podcast from The Center for BiosimilarsEpisode 10: The Patient Perspective on BiosimilarsRecently, Louis Tharp, the cofounder and executive director of the patient advocacy organization the Global Healthy Living Foundation, visited our studios in New Jersey to talk about how high drug costs impact patients with rheumatic diseases, and how biosimilars can be part of the solution. What follows is a portion of our discussion about biologics, biosimilars, and the patient's viewpoint.
2018-06-0310 minNot So Different: A Podcast from The Center for BiosimilarsEpisode 8: Medicare and BiosimilarsThis week on the podcast, we’re pleased to welcome our guest, Leigh Purvis, MPA. Purvis is the director of health services research at AARP’s public policy institute. Her work focuses on a variety of prescription drug and mental health-related issue, with an emphasis on prescription drug pricing, biologic drugs, and prescription drug coverage under Medicare.
Purvis joined us by phone to talk about the challenges that Medicare beneficiaries face with respect to obtaining and paying for their biologic drugs, and about the policies that AARP hopes to see implemented in the days ahead.
2018-05-0608 minNot So Different: A Podcast from The Center for BiosimilarsEpisode 7: Oncology BiosimilarsThis week, we're delving into the world of supportive care and anticancer biosimilars with an oncology expert, Robert M. Rifkin, MD, FACP.
2018-04-2205 minNot So Different: A Podcast from The Center for BiosimilarsEpisode 6: The Nebraska Rheumatology SocietyToday, we're talking about state-level legislation concerning the substitution of interchangeable biosimilars, and how 1 specific piece of biosimilars-focused legislation led to the formation of the Nebraska Rheumatology Society. Our guest this week is Marcus Snow, MD, a rheumatologist at the University of Nebraska Medical Center, and assistant professor of rheumatology at the University of Nebraska.
2018-04-0510 min
Not So Different: A Podcast from The Center for BiosimilarsEpisode 5: Policy and BiosimilarsEpisode 5: Policy and Biosimilars by The Center for Biosimilars
2018-03-2013 minNot So Different: A Podcast from The Center for BiosimilarsEpisode 4: Creating a Vibrant Biosimilars MarketEpisode 4: Creating a Vibrant Biosimilars Market by The Center for Biosimilars
2018-03-1613 min